Evolution of T-cell fitness through AML progression: enhanced bispecific T-cell engager-mediated function of bone marrow T cells at remission compared to initial diagnosis and relapse

Leukemia. 2024 Aug 22. doi: 10.1038/s41375-024-02387-4. Online ahead of print.

Maryam Kazerani^{1

2}, Anetta Marcinek^{1

2}, Nora Philipp^{1

2}, Bettina Brauchle^{1

2}, Jonathan Jonas Taylor^{1

2}, Helena Domínguez Moreno³, Andrea Terrasi³, Benjamin Tast^{1

2}, Lisa Rohrbacher^{1

2}, Yingshuai Wang^{1

2}, Maximilian Warm², Alica-Joana Emhardt², Giulia Magno², Karsten Spiekermann^{2

4

5}, Tobias Herold², Tobias Straub⁶, Sebastian Theurich^{1

2}, Gunnar Schotta³, Roman Kischel^{7

8}, Veit L Bücklein^{1

2}, Marion Subklewe^{9

10

11}

¹ Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.
² Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
³ Division of Molecular Biology, Biomedical Center, Faculty of Medicine, LMU Munich, Martinsried, Germany.
⁴ Experimental Leukemia and Lymphoma Research (ELLF), Department of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany.
⁵ German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
⁶ Bioinformatics Unit, Biomedical Center, LMU Munich, Martinsried, Germany.
⁷ Amgen Research (Munich) GmbH, Munich, Germany.
⁸ AMGEN Inc., Thousand Oaks, CA, USA.
⁹ Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. Marion.Subklewe@med.uni-muenchen.de.
¹⁰ Department of Medicine III, University Hospital, LMU Munich, Munich, Germany. Marion.Subklewe@med.uni-muenchen.de.
¹¹ German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany. Marion.Subklewe@med.uni-muenchen.de.

No abstract available

Grants and funding